Womens Health Investment Outlook 2026

50. Euronews. (2025, February 13). How are fertility treatments handled around the EU? https://www.euronews.com/my- europe/2025/02/13/how-are-fertility-treatments-handled-around-the-eu 51. GlobalData. (2019, September 30). Female infertility – opportunity analysis and forecasts to 2028. https://www.globaldata.com/store/report/female-infertility-opportunity-analysis-and-forecasts-to-2028/ 52. Yang, R., et al. (2021). Comparison of the long-acting GnRH agonist follicular protocol with the GnRH antagonist protocol in women undergoing in vitro fertilization: A systematic review and meta-analysis. Advances in Therapy, 38(5), 2027– 2037. https://doi.org/10.1007/s12325-020-01612-7 53. Nataraja, S., et al. (2021). Discovery and preclinical development of orally active small molecules that exhibit highly selective follicle stimulating hormone receptor agonism. Frontiers in Pharmacology, 11, 602593. https://doi.org/10.3389/ fphar.2020.602593 54. Raut, S. Y., et al. (2023). Engineered nano-carrier systems for the oral targeted delivery of follicle stimulating hormone: Development, characterization, and assessment of in vitro and in vivo performance and targetability. International Journal of Pharmaceutics, 637, 122868. https://doi.org/10.1016/j.ijpharm.2023.122868 55. Celmatix. (n.d.). Our groundbreaking drug pipeline is the future of women’s health. Retrieved November 12, 2025, from https://www.celmatix.com/pipeline 56. Ebert, E. (2025, January 30). FDA grants clearance for phase 3 trial of Fertilo, an iPSC-based fertility treatment. Contemporary OB/GYN. https://www.contemporaryobgyn.net/view/fda-grants-clearance-for-phase-3-trial-of-fertilo-an- ipsc-based-fertility-treatment 57. Arbat, A., et al. (2024, July). O-027 Efficacy results from the phase II randomized clinical trial: OXO-001 in infertile women undergoing egg donation IVF/ICSI. Human Reproduction, 39(Supplement 1), deae108.027. https://doi.org/10.1093/ humrep/deae108.027 58. GlobalData. (2019, September 30). Female infertility – opportunity analysis and forecasts to 2028. https://www.globaldata.com/store/report/female-infertility-opportunity-analysis-and-forecasts-to-2028/ 59. La Forgia, A., & Bodner, J. (2023, July). Corporate ownership and firm performance: Evidence from fertility clinics. Academy of Management Proceedings, 2023(1), 11712. https://doi.org/10.5465/AMPROC.2023.11712abstract 60. Peipert, B. J., et al. (2022). Impact of in vitro fertilization state mandates for third party insurance coverage in the United States: A review and critical assessment. Reproductive Biology and Endocrinology, 20, 111. https://doi.org/10.1186/ s12958-022-00984-5 61. World Health Organization. (2023, April 4). 1 in 6 people globally affected by infertility [Press release]. https://www.who. int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility 62. The analysis used the following sources: Latin American Registry; European Society of Human Reproduction and Embryology (ESHRE); Canadian Assisted Reproductive Technologies Register (CARTR BORN); Centers for Disease Control and Prevention, Society for Assisted Reproductive Technology (CDC SART); International Journal for Equity in Health; Fertility Europe; United Arab Emirates (UAE) Government Portal; National Institutes of Health (NIH); University of New South Wales; Colliers; Singapore Ministry of Health; market participant interviews. 63. Full analyses are available at: Detailed analyses: Areas prime for investment. https://reports.weforum.org/docs/WHIO_ APPENDIX_C_FIGURES.pptx 64. National Institutes of Health. (2025, June 17). Funding for various Research, Condition, and Disease Categories (RCDC). https://report.nih.gov/funding/categorical-spending#/ 65. Valle, I., et al. (2025). Antibody–drug conjugates in breast cancer: Mechanisms of resistance and future therapeutic perspectives. NPJ Breast Cancer, 11(1), 102. https://doi.org/10.1038/s41523-025-00829-5 66. International Agency for Research on Cancer. (n.d.). Cancer today. Retrieved November 12, 2025, from https://gco.iarc. who.int/today/ 67. Institute for Health Metrics and Evaluation. (n.d.). GBD results. Retrieved November 12, 2025, from https://vizhub. healthdata.org/gbd-results 68. Islami, F., et al. (2019). National and state estimates of lost earnings from cancer deaths in the United States. JAMA Oncology, 5(9), e191460. https://doi.org/10.1001/jamaoncol.2019.1460 69. Phase I/II assets: Early clinical-stage drug candidates being tested in humans for safety (Phase I) and preliminary efficacy (Phase II). 70. Medicare drug price negotiation: A US federal policy introduced under the 2022 Inflation Reduction Act that allows the government to negotiate prices directly with manufacturers for a limited number of high-cost prescription drugs covered under Medicare, the national health insurance programme for adults aged 65 and older. 71. Wheel. (2025, March 28). Women are leading the shift to virtual care—here’s what healthcare leaders need to know. https://www.wheel.com/blog/women-are-leading-the-shift-to-virtual-care 72. Seed. (n.d.). SBIR and STTR funding opportunities. Retrieved November 12, 2025, from https://seed.nih.gov/small- business-funding/find-funding/sbir-sttr-funding-opportunities 73. European Commission. (n.d.). Horizon 2020. Retrieved November 12, 2025, from https://research-and-innovation. ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-2020_en Women’s Health Investment Outlook 44